Jump Start Shared Medical Appointments for Diabetes With Weight Management

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

263 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-12

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed research will test a novel program that combines intensive weight management with shared (group) medical appointments for patients with diabetes. This research is important because diabetes is increasingly prevalent, it requires complex management by the provider and the patient, and weight loss is a critical component of its management. Adding weight management to shared medical appointments could potentially improve blood sugar control while reducing medications and their side effects such as low blood sugar.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study

NCT02471794

Type II Diabetes

COMPLETED NA

Comparative Effectiveness of Diabetes Shared Medical Appointment Models

NCT03590041

Diabetes Mellitus, Type 2

COMPLETED NA

Diabetes Self-Management & Support LIVE

NCT02040038

Diabetes Mellitus, Type 2

COMPLETED NA

Moderate or Extensive Carbohydrate Reduction in Risk Patients

NCT03090074

Glucose Metabolism Disorders

UNKNOWN NA

Diabetes Health Enhancement Program to Improve Health of People With Diabetes

NCT00291590

Diabetes

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anticipated Impacts on Veteran's Healthcare: Weight management is an important focus of VA as evidenced by its VA/DoD Clinical Practice Guideline and MOVE! program targeting overweight/obesity. VA is also committed to using group visits to increase the efficiency and effectiveness of health care delivery. The investigators aim to test a novel intervention that combines intensive weight and diabetes management using the SMA platform. This research addresses important missions to VA because diabetes is more prevalent in Veterans than in the general population, and because weight management is more challenging and complex in patients with diabetes. Project Background: SMAs involve groups of patients who share a common chronic condition and meet over time to receive education, self-management enhancement, and medication management to improve clinical outcomes. A systematic review by VA found that SMAs modestly improve glycemia in patients with diabetes. Although these SMA programs sometimes included diet and physical activity counseling, weight management was not a primary goal, and weight typically was not reduced. Instead, medication intensification was the primary strategy for improving glycemia, and this strategy can lead to weight gain.

For overweight patients with diabetes, weight loss is first-line therapy because it can improve glycemic control and because excess weight leads to poorer outcomes. Moreover, many antiglycemic medications cause weight gain and hypoglycemic events, which may counteract the potential macrovascular benefits of glycemic control. Dietary interventions, however, can lower weight and improve glycemic control while reducing antiglycemic medication needs and, therefore, subsequent risk for hypoglycemic episodes.

In prior research, the investigators induced weight loss and improved glycemic control while decreasing antiglycemic medications. A combination of an intensive weight management program with the diabetes management offered in SMAs has potential to further improve diabetes outcomes, reduce complications, decrease costs and increase health-related quality of life. Such a combined intervention is ideal for patients with diabetes because of their unique dietary considerations, and their need for careful glycemic and medication management during weight loss. Project Objectives: The investigators will examine whether an intensive, group-based weight management program followed by an SMA intervention (WM/SMA arm) is comparably effective (non-inferior) to the SMA intervention alone for improving glycemic control while using less antiglycemic medication and resulting in fewer hypoglycemic events and lower healthcare costs. Project Methods: 308 overweight VA outpatients with uncontrolled (hemoglobin A1c 8.0% or 7.5% or greater for those under 50) type 2 diabetes will participate in this RCT. Similar to prior SMAs, the SMA visits will occur every 4 weeks for 16 weeks and then every 8 weeks for 32 weeks for a total of 9 visits. Sessions will be led by a physician and trained interventionists, and will include educational topics related to diabetes management (including diet and physical activity), self-management training, and medication adjustment. Similar to the investigators' prior weight management trials, the WM/SMA group will meet every 2 weeks for 16 weeks and then every 8 weeks for 32 weeks for a total of 13 visits. The weight management program will focus on a low carbohydrate dietary pattern because of its potential to lower glycemia, leading to reduced antiglycemic medication needs. After 16 weeks, meeting content will shift to the SMA intervention content but weight management will continue to be addressed at the meetings. The primary outcome is glycemic control assessed by hemoglobin A1c assessed at baseline and at 16, 32, and 48 weeks. Secondary outcomes include hypoglycemic events, changes in the antiglycemic medication regimen as assessed by a summary score, weight and healthcare costs. Diabetes-specific health-related quality of life and medication adherence will also be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Weight management/shared medical appointment (WM/SMA)

Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.

Group Type EXPERIMENTAL

Weight management

Intervention Type BEHAVIORAL

Weight management group visits using low-carbohydrate diet followed for weight management.

Shared medical appointments (SMA)

Intervention Type BEHAVIORAL

Diabetes management group visits for diabetes management.

Shared medical appointments (SMA)

Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.

Group Type ACTIVE_COMPARATOR

Shared medical appointments (SMA)

Intervention Type BEHAVIORAL

Diabetes management group visits for diabetes management.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weight management

Weight management group visits using low-carbohydrate diet followed for weight management.

Intervention Type BEHAVIORAL

Shared medical appointments (SMA)

Diabetes management group visits for diabetes management.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of type 2 diabetes,
* Hemoglobin A1c \>= 8.0% or , \>= 7.5 for those less than 50
* BMI \>= 27 kg/m2,
* Interest in losing weight,
* Agrees to attend regular visits per study protocol,
* Has access to reliable transportation,
* Has a VAMC provider.

Exclusion Criteria

* Age \>= 75 years old,
* Hemoglobinopathy that interferes with measurement of hemoglobin A1c,
* Certain chronic or unstable diseases that may put the participant at increased risk. These include the following:

* Kidney disease (serum creatinine \>1.5 mg/dL in men, \>1.3 mg/dL in women),
* Type 1 diabetes,
* Unstable CHD (unstable angina, current/active coronary ischemia workup),
* Blood pressure 160/100 mm Hg,
* Fasting triglycerides 600 mg/dL,
* Fasting serum LDL-C 190 mg/dL,
* Pregnancy, breastfeeding, or lack of birth control if premenopausal,
* Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g. illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year),
* Enrollment in another research study that might affect the main outcomes of this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No